However, in the current pandemic, it’s essential that every dose is available for administration as quickly as possible. In a traditional drug supply chain, finished product may be stored for weeks or months until it is needed to meet public health requirements. This means that every batch made in our supply network must meet the same exacting production and quality standards.Īt every stage of the production process there is a continuous demand to test, record, analyse, report, confirm and verify. Our work here is not done.ĪstraZeneca takes responsibility for the safety, effectiveness and quality of all the COVID-19 vaccine made in our global supply network of manufacturing facilities across Europe, North, Central and South America, Asia and Australia. We continue to strive for even greater efficiency in vaccine production for combating the pandemic, and we are already looking beyond 2021 to identify global needs for COVID-19 vaccine after the pandemic. This means that teams are using every available moment to analyse data in real-time, validate results, complete essential vaccine release paperwork, and get trucks on the road around the world to take consignments to government distribution hubs once all quality requirements are satisfied.
Multiple manufacturing and testing processes are now carried out in parallel instead of consecutively – saving months of time compared to a traditional vaccine manufacturing process. In addition to rapidly building a team of hundreds of highly skilled workers from across nearly every part of our company and bringing in leading experts from our broader industry, we are doing everything in our power to accelerate and optimise the supply, production, testing and delivery processes. The successful start of vaccinations in the initial countries where it has been authorised for emergency supply is just the beginning for AstraZeneca. From there, governments and multilateral organisations with whom we have formed agreements will ensure fair allocation and distribution of the vaccine within their countries and regions.Īs part of our commitment to providing broad and equitable access to COVID-19 vaccine, AstraZeneca will also supply the COVAX Facility, led by GAVI, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organisation (WHO), which will distribute vaccine to low- and middle-income countries. AstraZeneca will deliver up to 3 billion doses of COVID-19 vaccine across the globe by the end of 2021 - which will be just 18 months after the company first partnered with the University of Oxford to develop and manufacture the vaccine.įollowing a multi-stage manufacturing and quality testing process, batches will be delivered to distribution hubs across the globe.
0 kommentar(er)
